PILA PHARMA is a clinical stage biotech company pioneering development of an oral TRPV1-antagonist as a potential first-in-class treatment for obesity and diabetes.
FIRST SUBJECTS DOSED IN SAFETY PART 1 OF PP-CT04, A CLINICAL TRIAL IN PEOPLE LIVING WITH OBESITY
Find the link to the Press Releases (In English) here
[September 30 2026 17:15:00 CEST]
PILA PHARMA AB Interim Report First Half Year 2026, 1 January – 30 June 2026
Find the link to the report (In English) here
CEO Gustav H. Gram presentation on PILA PHARMA’s half-year report
[August 27, 2026, at 11:00 AM (Sweden time / CEST)]
Find the link to the presentation (In English) here
